Effector Therapeutics Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Public

  • Employees
  • 14


  • Stock Symbol
  • EFTR

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $1.71
  • (As of Friday Closing)

Effector Therapeutics General Information


eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs).

Contact Information

Formerly Known As
Locust Walk Acquisition Corp
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Other Devices and Supplies
Therapeutic Devices
Stock Exchange
Corporate Office
  • 142 North Cedros Avenue
  • Suite B
  • Solana Beach, CA 92075
  • United States
+1 (858) 000-0000

Effector Therapeutics Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Effector Therapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.71 $1.78 $1.60 - $37.00 $7.12M 3.42M 375K -$16.37

Effector Therapeutics Financials Summary

In Thousands,
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 32,902 32,902 5,174 299,301
Revenue 0 0 0 0
EBITDA (33,753) (33,753) (20,800) 17,580
Net Income (35,811) (35,811) (22,665) 15,798
Total Assets 20,544 20,544 29,077 54,056
Total Debt 20,545 20,545 20,281 20,030
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Effector Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Effector Therapeutics‘s full profile, request access.

Request a free trial

Effector Therapeutics Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
% Owned

This information is available in the PitchBook Platform. To explore Effector Therapeutics‘s full profile, request access.

Request a free trial

Effector Therapeutics Comparisons

HQ Location
Total Raised
Post Valuation
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new c
Drug Discovery
Solana Beach, CA
14 As of 2023
00000000 00000


magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco labori
0000 000000000
Cambridge, MA
0000 As of 0000
00000000 00000


nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. D
Paris, France
000 As of 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Effector Therapeutics Competitors (45)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sarepta Therapeutics Formerly VC-backed Cambridge, MA 0000 00000 00000000 00000
Cellectis Formerly VC-backed Paris, France 000 00000 0000
Anokion Venture Capital-Backed Ecublens, Switzerland 00 00000 000000000000 00000
Sorrento Therapeutics Formerly VC-backed San Diego, CA 000 00000 0000000000.
Sharp Therapeutics Venture Capital-Backed Pittsburgh, PA 0 00.000 0000000000 0 00.000
You’re viewing 5 of 45 competitors. Get the full list »

Effector Therapeutics Executive Team (15)

Name Title Board Seat Contact Info
Stephen Worland Ph.D Chief Executive Officer, President and Board Member
Michael Byrnes Chief Financial Officer, Finance
Mayank Gandhi MD Chief Business Officer
Davide Ruggero Ph.D Co-Founder
Douglas Warner MD Chief Medical Officer
You’re viewing 5 of 15 executive team members. Get the full list »

Effector Therapeutics Board Members (21)

Name Representing Role Since
Barbara Klencke MD Self Board Member 000 0000
Brian Gallagher Ph.D Abingworth Chairman & Board Member 000 0000
Caroline Loewy Effector Therapeutics Board Member 000 0000
Christopher Ehrlich Self Board Member 000 0000
Denis Patrick Ph.D Pfizer Ventures Board Member 000 0000
You’re viewing 5 of 21 board members. Get the full list »

Effector Therapeutics Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Effector Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Locust Walk Acquisition 25-Aug-2021 0000000000 Special Purpose Acquisition Company (SPAC) 0000000 0
To view Effector Therapeutics’s complete acquisitions history, request access »

Effector Therapeutics FAQs

  • When was Effector Therapeutics founded?

    Effector Therapeutics was founded in 2012.

  • Who is the founder of Effector Therapeutics?

    Siegfried Reich Ph.D, Davide Ruggero Ph.D, Kevin Eastwood, Kevan Shokat Ph.D, and James Appleman Ph.D are the founders of Effector Therapeutics.

  • Who is the CEO of Effector Therapeutics?

    Stephen Worland Ph.D is the CEO of Effector Therapeutics.

  • Where is Effector Therapeutics headquartered?

    Effector Therapeutics is headquartered in Solana Beach, CA.

  • What is the size of Effector Therapeutics?

    Effector Therapeutics has 14 total employees.

  • What industry is Effector Therapeutics in?

    Effector Therapeutics’s primary industry is Drug Discovery.

  • Is Effector Therapeutics a private or public company?

    Effector Therapeutics is a Public company.

  • What is Effector Therapeutics’s stock symbol?

    The ticker symbol for Effector Therapeutics is EFTR.

  • What is the current stock price of Effector Therapeutics?

    As of 19-Apr-2024 the stock price of Effector Therapeutics is $1.71.

  • What is the current market cap of Effector Therapeutics?

    The current market capitalization of Effector Therapeutics is $7.12M.

  • Who are Effector Therapeutics’s competitors?

    Sarepta Therapeutics, Cellectis, Anokion, Sorrento Therapeutics, and Sharp Therapeutics are some of the 45 competitors of Effector Therapeutics.

  • What is Effector Therapeutics’s annual earnings per share (EPS)?

    Effector Therapeutics’s EPS for 12 months was -$16.37.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »